• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Clearant Expands Adoption of Clearant Process With Surgeon Community Programs at the American Orthopaedic Society for Sports Medicine Conference

Posted on: Monday, 26 June 2006, 09:00 CDT

Leading Orthopaedic Surgeons Join Clearant in Educational Symposium Addressing Safety and Sterilization of Allograft Implants, Effectiveness of the Clearant Process

Clearant, Inc. (OTCBB:CLRI) today announced that it will continue to increase the adoption of Clearant Process(TM) tissue implants among the surgeon community with a major presence at the upcoming American Orthopaedic Society for Sports Medicine (AOSSM) Annual Conference held from June 29 to July 2 at the Hershey(R) Lodge & Convention Center in Hershey, PA. Through educational, sales and marketing initiatives at the conference, Clearant will demonstrate the benefits of pathogen inactivation in allograft tissue using the Clearant Process. The Clearant Process is a ground-breaking sterilization method that substantially reduces all types of pathogens in biological products while maintaining the functionality integrity of the graft.

Clearant will hold an educational symposium on June 30 featuring several of the nation's leading orthopaedic surgeons who routinely implant Clearant Process tissue implants. In the forum, Dr. Phil Davidson of Tampa Bay Orthopaedic Specialists, Dr. Ty Endean of the Sports Institute of Tucson, and Dr. Chris Larson of Allina Medical Group of Minnesota will address the current environment in the safety of human allografts and review the processes that are available for the cleaning and sterilization of these grafts. The panel will provide an overview of the advantages and disadvantages of allograft use, the risk and instance of implant-related infection, current and new methods for achieving sterility in allograft tissue, and recent research.

"As we announced recently, Clearant has begun aggressively targeting key orthopaedic surgeons and hospitals that most actively perform procedures that could benefit from the Clearant Process," said Clearant Chief Executive Officer Alain Delongchamp. "As a result, Clearant has started to increase its profile within the surgeon community just as the critical need for allograft sterilization receives increasing national attention due to unfortunate cases of viral and bacterial infections. The response from orthopaedic surgeons to the Clearant Process has been overwhelmingly positive as we continue to provide compelling research showing that allografts treated with the Clearant Process demonstrate comparable strength and functionality to conventional allografts while significantly reducing the risk of infection."

For more information about the symposium or to gain admittance, please contact Marcie Chan at 310-479-4570, ext. 249 or mchan@clearant.com.

About Clearant, Inc.

Clearant, Inc. is a leader in pathogen inactivation for biological products. Clearant has developed the patent-protected Clearant Process, which substantially reduces all types of pathogens in biological products while maintaining the functionality of the underlying protein. The Company plans to distribute directly to surgeons, hospitals and clinics Clearant Process sterile implants starting mid 2006; in addition, Clearant continues to license the Clearant Process and provides its patented sterilization services to tissue banks and other biological products manufacturers. As of the end of 1Q 2006, Clearant had 10 license and service agreements with tissue banks. To date more than 8,000 patients have been successfully implanted with Clearant Process sterile implants supplied by one of the Company's licensed partners. Whereas various competing sterilization methods only kill specific types of pathogens (such as bacteria or lipid-enveloped viruses) for specific products, the Clearant Process reduces all types of pathogens for products across many market segments including tissue implants, plasma proteins, recombinant products, medical devices and blood products. Also, the Clearant Process can be applied at various stages of product processing and/or manufacturing, including in the final packaging. For more information, please visit www.clearant.com.

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995, in particular statements regarding surgeons strongly recommending the use of implants with tissue treated by the CLEARANT PROCESS, and the conclusions from a study by surgeons to build demand for sterilized tissue. These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control, which may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited operating history, difficulty in developing, exploiting and protecting proprietary technologies, results of additional clinical studies, efficacy of the technology, intense competition and substantial regulation in the biotechnology industry, and additional risks discussed in the company's filings with the SEC, available on the SEC web site http://www.sec.gov.

Source: Business Wire

More News in this Category